Mutated IDH1 is a Favorable Prognostic Factor for Type 2 Gliomatosis Cerebri

Overview

Journal Brain Pathol

Date 2011 Sep 21

PMID 21929658

Citations 10

Authors

Mi Jung Kwon

Sung Tae Kim

Mi Jeong Kwon

Doo-Sik Kong

Dageun Lee

Sanghui Park

So Young Kang

Ji-Young Song

Do-Hyun Nam

Yukinari Kato

Yoon-La Choi

Yeon-Lim Suh

Affiliations

Soon will be listed here.

Abstract

The prognostic significance of IDH1 mutations has been demonstrated in gliomas. It is unclear whether IDH1 mutation is also a prognostic factor in gliomatosis cerebri (GC). Primary GCs can be grouped into type 1 GCs, which have the classical diffuse growth pattern without mass formation, and type 2 GCs, which form neoplastic masses in addition to classic diffuse lesions. In this study, the prognostic relevance of IDH1/2 mutations in 74 GCs (43 type 1 and 31 type 2) was evaluated. We detected 33 (44.6%) IDH1 mutations, including R132H and R132S, by bidirectional Sanger sequencing. No mutations were detected in IDH2. The percentage of 2-year overall survival for wild-type IDH1 patients was 46 vs. 72% for patients with IDH1-mutated tumors. Mutations of IDH1 were strongly correlated with both increased overall survival (OS) and progression-free survival (PFS) in patients with type 2 GCs, and IDH1 mutations were also an independent prognostic factor predicting increased OS and PFS in type 2 GC patients in multivariate analysis. However, IDH1 mutations did not correlate with survival outcomes in patients with type 1 GCs. Finally, the subgroup of GC, which has IDH1 wild-type and additional solid component showed the worst prognosis.

Citing Articles

Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases.

Kwon M, Kang S, Cho H, Lee J, Kim S, Suh Y Brain Pathol. 2019; 30(2):235-245.

PMID: 31435963 PMC: 8018049. DOI: 10.1111/bpa.12782.

A Pediatric Case of Diffuse Glioma Diagnosed at Autopsy.

Ross J, Olar A, Fuller C Acad Forensic Pathol. 2019; 7(4):657-666.

PMID: 31240015 PMC: 6474431. DOI: 10.23907/2017.056.

Genomic copy number gains of ErbB family members predict poor clinical outcomes in glioma patients.

Liu R, Qu Y, Chen L, Pu J, Ma S, Zhang X Oncotarget. 2017; 8(54):92275-92288.

PMID: 29190914 PMC: 5696180. DOI: 10.18632/oncotarget.21228.

Gliomatosis Cerebri: Current Understanding and Controversies.

Ranjan S, Warren K Front Oncol. 2017; 7:165.

PMID: 28824876 PMC: 5545748. DOI: 10.3389/fonc.2017.00165.

Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6.

Ogasawara S, Fujii Y, Kaneko M, Oki H, Sabit H, Nakada M Monoclon Antib Immunodiagn Immunother. 2016; 35(5):254-258.

PMID: 27788029 PMC: 5160166. DOI: 10.1089/mab.2016.0037.

References

Desestret V, Ciccarino P, Ducray F, Criniere E, Boisselier B, Labussiere M . Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression. J Neurooncol. 2011; 105(2):219-24. DOI: 10.1007/s11060-011-0587-4. View

Desclee P, Rommel D, Hernalsteen D, Godfraind C, De Coene B, Cosnard G . Gliomatosis cerebri, imaging findings of 12 cases. J Neuroradiol. 2010; 37(3):148-58. DOI: 10.1016/j.neurad.2009.12.001. View

Kattar M, Kupsky W, Shimoyama R, Vo T, Olson M, Bargar G . Clonal analysis of gliomas. Hum Pathol. 1997; 28(10):1166-79. DOI: 10.1016/s0046-8177(97)90255-0. View

Villano J, Seery T, Bressler L . Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol. 2009; 64(4):647-55. DOI: 10.1007/s00280-009-1050-5. View

Seiz M, Tuettenberg J, Meyer J, Essig M, Schmieder K, Mawrin C . Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol. 2010; 120(2):261-7. DOI: 10.1007/s00401-010-0701-2. View

Jennings M, Frenchman M, Shehab T, Johnson M, CREASY J, Laporte K . Gliomatosis cerebri presenting as intractable epilepsy during early childhood. J Child Neurol. 1995; 10(1):37-45. DOI: 10.1177/088307389501000111. View

Inoue T, Kumabe T, Kanamori M, Sonoda Y, Watanabe M, Tominaga T . Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases. Neurosurg Rev. 2011; 34(2):197-208. DOI: 10.1007/s10143-010-0306-1. View

Narasimhaiah D, Miquel C, Verhamme E, Desclee P, Cosnard G, Godfraind C . IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri. Neuropathology. 2011; 32(1):30-7. DOI: 10.1111/j.1440-1789.2011.01216.x. View

Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Kaneko M . Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol. 2011; 28(2):115-23. DOI: 10.1007/s10014-011-0023-7. View

10.

Yen K, Bittinger M, Su S, Fantin V . Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene. 2010; 29(49):6409-17. DOI: 10.1038/onc.2010.444. View

11.

Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J . Initial chemotherapy in gliomatosis cerebri. Neurology. 2004; 63(2):270-5. DOI: 10.1212/01.wnl.0000129985.39973.e4. View

12.

Gerber D, Grossman S, Zeltzman M, Parisi M, Kleinberg L . The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol. 2006; 9(1):47-52. PMC: 1828105. DOI: 10.1215/15228517-2006-024. View

13.

van Nifterik K, van den Berg J, van der Meide W, Ameziane N, Wedekind L, Steenbergen R . Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. Br J Cancer. 2010; 103(1):29-35. PMC: 2905289. DOI: 10.1038/sj.bjc.6605712. View

14.

Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D . Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2009; 20(1):245-54. PMC: 8094636. DOI: 10.1111/j.1750-3639.2009.00352.x. View

15.

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A . Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009; 118(4):469-74. DOI: 10.1007/s00401-009-0561-9. View

16.

Felsberg J, Wolter M, Seul H, Friedensdorf B, Goppert M, Sabel M . Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol. 2010; 119(4):501-7. DOI: 10.1007/s00401-010-0647-4. View

17.

Mawrin C, Kirches E, Schneider-Stock R, Scherlach C, Vorwerk C, von Deimling A . Analysis of TP53 and PTEN in gliomatosis cerebri. Acta Neuropathol. 2003; 105(6):529-36. DOI: 10.1007/s00401-003-0674-5. View

18.

Shapiro J, Yung W, Shapiro W . Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res. 1981; 41(6):2349-59. View

19.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S . The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007; 11(45):iii-iv, ix-221. DOI: 10.3310/hta11450. View

20.

Bonavia R, Inda M, Cavenee W, Furnari F . Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 2011; 71(12):4055-60. PMC: 3117065. DOI: 10.1158/0008-5472.CAN-11-0153. View